Sign In
Buy RVTY
$101.07
+0.680 (+0.677%)
At Close: Jun 03, 2026
Revvity (RVTY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
11:05am, Monday, 21'st Jul 2025
Revvity (RVTY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revvity to Hold Earnings Call on Monday, July 28, 2025
08:00am, Monday, 07'th Jul 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its second quarter 2025 financial results prior to market open on Monday, July 28, 2025. The Company w
Revvity Introduces New IVD Reference Standards for Monitoring Oncology Diagnostic Testing Workflows
08:00am, Monday, 02'nd Jun 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced the launch of three Mimix™ reference standards for IVD use, designed for monitoring of next-generation sequencing (NGS) o
RVTY Stock Falls Despite the Latest Launch of Automated Instrument
11:51am, Friday, 23'rd May 2025
Revvity unveils IDS i20, a fully automated immunodiagnostics platform designed to enhance lab efficiency and expand specialty testing.
Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing
08:00am, Monday, 19'th May 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced the launch of its new IDS i20™ analytical random access platform from EUROIMMUN, enabling full automation of chemilumines
Revvity: Despite Facing Multiple Headwinds, Shares Are A Buy
10:35am, Friday, 09'th May 2025
Revvity faces multiple headwinds including declining biotech funding, regulatory uncertainty, and reduced academic research budgets. Despite challenges, Revvity's Q1 results beat expectations and the
RVTY Rises as Q1 Earnings & Sales Beat Estimates, '25 Sales View Up
02:20pm, Monday, 28'th Apr 2025
Revvity's first-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales.
Revvity, Inc. (RVTY) Q1 2025 Earnings Call Transcript
11:49am, Monday, 28'th Apr 2025
Revvity, Inc. (NYSE:RVTY ) Q1 2025 Earnings Conference Call April 28, 2025 8:00 AM ET Company Participants Steve Willoughby - Senior Vice President, Investor Relations Prahlad Singh - President & Chie
Revvity (RVTY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
10:31am, Monday, 28'th Apr 2025
While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare t
Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop
09:14am, Monday, 28'th Apr 2025
Revvity Inc. RVTY stock is trading higher on Monday after the company reported better-than-expected first-quarter 2025 earnings.
Revvity (RVTY) Beats Q1 Earnings and Revenue Estimates
08:15am, Monday, 28'th Apr 2025
Revvity (RVTY) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $0.98 per share a year ago.
Revvity beats quarterly estimates on steady demand for medical equipment
07:32am, Monday, 28'th Apr 2025
Revvity reported first-quarter results above Wall Street estimates and maintained its full-year profit forecast on Monday, helped by steady demand from biotech clients for medical equipment used for d
Revvity Announces Financial Results for the First Quarter of 2025
06:00am, Monday, 28'th Apr 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended March 30, 2025. The Company reported GAAP earnings per share of $0.35, as comp
Why Revvity (RVTY) Could Beat Earnings Estimates Again
01:15pm, Friday, 25'th Apr 2025
Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Segmental Performance to Drive RVTY's Q1 Earnings: Is a Beat Likely?
09:00am, Friday, 25'th Apr 2025
RVTY's first-quarter results are likely to reflect decent performance in the Diagnostics segment. The Life Sciences segment is likely to have faced continued challenges in China.
